These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9399032)

  • 21. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.
    Loghman-Adham M; Soto CE; Inagami T; Cassis L
    Am J Physiol Renal Physiol; 2004 Oct; 287(4):F775-88. PubMed ID: 15187005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone and renin in relation to surrogate measures of sympathetic activity: the SABPA study.
    Gafane-Matemane LF; van Rooyen JM; Schutte R; Schutte AE
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):34-40. PubMed ID: 30720841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension in polycystic kidney disease type 1 and 2 and its effect on the age of onset of end-stage renal disease.
    Torra R; Badenas C; Pérez L; Estivill X; Darnell A
    Contrib Nephrol; 1997; 122():28-30. PubMed ID: 9399033
    [No Abstract]   [Full Text] [Related]  

  • 24. Some aspects of kidney function, the renin-aldosterone system and sympathetic activity in essential hypertension.
    Pedersen EB
    Acta Med Scand Suppl; 1980; 636():1-66. PubMed ID: 6103641
    [No Abstract]   [Full Text] [Related]  

  • 25. Screening of QTc interval and global autonomic activity in autosomal dominant polycystic kidney disease and atherosclerotic renal artery stenosis hypertensive patients.
    Lai S; Perrotta AM; Bagordo D; Mazzaferro S; Menè P; Gigante A; Tinti F; Galani A; Cianci R
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6333-6338. PubMed ID: 34730214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
    Masoumi A; Elhassan E; Schrier RW
    Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
    Wang D; Strandgaard S
    J Hypertens; 1997 Sep; 15(9):925-33. PubMed ID: 9321739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sympathetic nerve hyperactivity in high-renin hypertension effects of saralasin infusion.
    DeQuattro V; Barbour BH; Campese V; Finck EJ; Miano L; Esler M
    Mayo Clin Proc; 1977 Jun; 52(6):369-73. PubMed ID: 865132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of sympathetic nerve activity on renal haemodynamics and release of renin. A preliminary communication.
    Lörelius LE; Löfroth PO; Wiklund L; Mörlin C; Aberg H
    Ups J Med Sci; 1976; 81(2):109-11. PubMed ID: 960290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension and renal injury in experimental polycystic kidney disease.
    Kennefick TM; Al-Nimri MA; Oyama TT; Thompson MM; Kelly FJ; Chapman JG; Anderson S
    Kidney Int; 1999 Dec; 56(6):2181-90. PubMed ID: 10594794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impaired control of plasma renin activity in hypertensive patients with end-stage renal disease due to chronic glomerulonephritis.
    Yasuda G; Nagasawa T; Umemura S; Shionoiri H; Ishii M
    Clin Nephrol; 1994 Nov; 42(5):300-8. PubMed ID: 7851031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responses of plasma catecholamines, renin-angiotensin-aldosterone system, and atrial natriuretic peptide to exercise in patients with essential hypertension.
    Kinugawa T; Endo A; Kato M; Kato T; Ahmmed GU; Omodani H; Osaki S; Ogino K; Hisatome I; Miyakoda H; Fujimoto Y; Yoshida A; Shigemasa C
    Cardiology; 1997; 88(3):238-45. PubMed ID: 9129844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects.
    Ecder T; Schrier RW
    J Am Soc Nephrol; 2001 Jan; 12(1):194-200. PubMed ID: 11134267
    [No Abstract]   [Full Text] [Related]  

  • 35. A novel interaction between sympathetic overactivity and aberrant regulation of renin by miR-181a in BPH/2J genetically hypertensive mice.
    Jackson KL; Marques FZ; Watson AM; Palma-Rigo K; Nguyen-Huu TP; Morris BJ; Charchar FJ; Davern PJ; Head GA
    Hypertension; 2013 Oct; 62(4):775-81. PubMed ID: 23897069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renin-aldosterone system in patients with hypertensive form of chronic glomerulonephritis and preserved renal function].
    Borovkova NIu; Borovkov NN; Sidnev BN
    Klin Med (Mosk); 2009; 87(8):61-3. PubMed ID: 19827534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive modulators during and after craniotomy: relation to postoperative hypertension.
    Olsen KS; Pedersen CB; Madsen JB; Ravn LI; Schifter S
    J Neurosurg Anesthesiol; 2002 Jul; 14(3):171-9. PubMed ID: 12172288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hemodynamics, renin and aldosterone following angiotensin II blockade and sodium chloride deficiency in hypertensive subjects].
    Beyer J; Liebau G; Steiner B; Schick K; Hayduk K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():212-3. PubMed ID: 613577
    [No Abstract]   [Full Text] [Related]  

  • 39. [The activities of the renin-angiotensin-aldosterone and sympathetic-adrenal systems during hemodialysis].
    Akopian AS; Koriakin MV; Golubov AA; Shevchenko AV
    Urol Nefrol (Mosk); 1991; (4):45-50. PubMed ID: 1659015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal sequelae of sympathetic hyperactivity].
    Watschinger B; Habicht A
    Wien Med Wochenschr; 2004; 154 Spec No 1(1):7-9. PubMed ID: 15346546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.